Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (816 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: typedetermine whetherto assessdiabetesassess the
  Phrases that lowered it: healthytabletvolunteerscrossoverfood
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 375 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 6.8% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 829 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 55.9% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 7.5% (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 55 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Primary purpose: basic science (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 7874 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 37158 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets NCT01055691 · started 2010 · scored riskier than 0% of active trials completed
• Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers NCT01459094 · started 2011 · scored riskier than 0% of active trials completed
• To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately NCT01535677 · started 2013 · scored riskier than 0% of active trials completed
• Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food NCT02039258 · started 2014 · scored riskier than 0% of active trials completed
• The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers NCT07396844 · started 2026 · scored riskier than 0% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.